Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sirolimus
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : Narrows Institute for Biomedical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans
Details : Sirolimus is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acanthosis Nigricans.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 23, 2025
Lead Product(s) : Sirolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Narrows Institute for Biomedical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naxitamab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Y-mAbs Therapeutics
Deal Size : $33.0 million
Deal Type : Licensing Agreement
Y-mAbs And Nobelpharma Sign DANYELZA® Deal for Japanese Market
Details : The agreement aims for the development and commercialization in Japan of Danyelza (naxitamab) for high-risk neuroblastoma and, upon agreement by the parties, potentially relapsed osteosarcoma.
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : $2.0 million
November 04, 2024
Lead Product(s) : Naxitamab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Y-mAbs Therapeutics
Deal Size : $33.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Fibroblast Growth Factor 2
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase I/ Phase II
Recipient : D. Bradley Welling
Deal Size : Inapplicable
Deal Type : Inapplicable
In-office Repair of Chronic Tympanic Membrane Perforations
Details : Fibroblast Growth Factor 2 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Tympanic Membrane Perforation.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 07, 2024
Lead Product(s) : Fibroblast Growth Factor 2
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase I/ Phase II
Recipient : D. Bradley Welling
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sargramostim
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Partner Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Partner Therapeutics' Leukine® (sargramostim) Approved in Japan for aPAP
Details : Sargmalin (sargramostim) is a glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF). It is approved for autoimmune pulmonary alveolar proteinosis.
Product Name : Sargmalin
Product Type : Protein
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : Sargramostim
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Partner Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hyftor (sirolimus) is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in patients with age of 6 years and older. Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cyto...
Product Name : Hyftor
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HYFTOR™ (sirolimus topical gel) 0.2% is the first and only clear topical medication approved by the FDA to treat facial angiofibroma associated with TSC in adults and children 6 years of age and older.
Product Name : Hyftor
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 30, 2022
Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NPC-12Y
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
Details : NPC-12Y is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tuberous Sclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 10, 2022
Lead Product(s) : NPC-12Y
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosphenytoin Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NPC-06 to Pain Associated With Acute Herpes Zoster
Details : NPC-06 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Pain-associated with Herpes Zoster.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 29, 2022
Lead Product(s) : Fosphenytoin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HYFTOR™ (sirolimus topical gel) 0.2% is the first and only clear topical medication approved by the FDA to treat facial angiofibroma associated with TSC in adults and children 6 years of age and older.
Product Name : Hyftor
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 25, 2022
Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Nobelpharma's HYFTOR™ (sirolimus topical gel) 0.2%
Details : Hyftor (sirolimus) 0.2% is the first and only clear topical medication approved by the FDA to treat facial angiofibroma associated with TSC in adults and children 6 years of age and older.
Product Name : Hyftor
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable